EUVIMEDEUVIMED entdecken
Open Access

Incorporation of Metabolic Dysfunction‐Associated Steatotic Liver Disease in the Health Stage of Cardiovascular‐Kidney‐Metabolic Syndrome Improves Predictive Ability for Coronary Artery Disease in a Japanese General Population

Wataru Kawaharata, Marenao Tanaka iD, Tatsuya Sato iD, Yukinori Akiyama, Itaru Hosaka, Hiroki Aida, Rie Matsumori, Kei Nakata iD, Keitaro Nishizawa iD, Toru Suzuki, Hidemichi Kouzu iD, Nagisa Hanawa und 1 weitere

Journal of the American Heart Association · 19.08.2025 · 14 (16)

DOI: 10.1161/jaha.125.043173 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the American Heart Association, erschienen am 19.08.2025. Verfasst von Wataru Kawaharata und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiovascular-Kidney-Metabolic Medicine, Department of Internal Medicine Sapporo Medical University School of Medicine Sapporo Japan. Hauptthemen laut MEDLINE: Metabolic Syndrome, Coronary Artery Disease, Cardio-Renal Syndrome, Fatty Liver. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cardiovascular‐kidney‐metabolic (CKM) syndrome is a recently proposed condition encompassing metabolic dysfunction, chronic kidney disease, and cardiovascular diseases including coronary artery disease (CAD). Although concomitant metabolic dysfunction‐associated steatotic liver disease (MASLD) exacerbates CKM syndrome, MASLD is not included in the original stratification (stages 0–3) for predicting cardiovascular disease (stage 4).

Methods

We investigated whether the addition of MASLD in the original health stage of CKM syndrome improves the risk stratification of CAD in Japanese participants who underwent annual health checkups. A total of 18 358 participants were categorized by the original health stages (stages 0–3) or modified health stages incorporating MASLD without chronic kidney disease in stage 2 and MASLD with chronic kidney disease in stage 3 to analyze the predictive ability for CAD during a 10‐year period.

Results

Kaplan–Meier survival curve analysis showed that the modified classification more effectively stratified the risk of CAD than did the original CKM health stage. In Cox hazard proportional analyses after adjustment of confounders, hazard ratios in the original and modified stages 2/3 were 1.63 (95% CI, 1.27–2.11; P

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Metabolic SyndromeCoronary Artery DiseaseCardio-Renal SyndromeFatty LiverHumansMaleFemaleMiddle AgedJapanRisk AssessmentAgedRisk FactorsPrognosisPredictive Value of TestsEast Asian People

Stichwörter der Autor:innen

cardiovascular‐kidney‐metabolic syndromecoronary artery diseasemachine learningsteatotic liver disease

Autor:innen und Institutionen

  • Division of Cardiovascular-Kidney-Metabolic Medicine, Department of Internal Medicine Sapporo Medical University School of Medicine Sapporo Japan.
  • Tanaka Medical Clinic Yoichi Japan.
  • Division of Cellular Physiology and Signal Transduction, Department of Physiology Sapporo Medical University School of Medicine Sapporo Japan.
  • Department of Neurosurgery Sapporo Medical University School of Medicine Sapporo Japan.
  • Division of Cardiovascular Surgery, Department of Surgery Sapporo Medical University School of Medicine Sapporo Japan.
  • Division of Public Health, Department of Social Medicine Sapporo Medical University School of Medicine Sapporo Japan.

ORCID-Profile: Marenao Tanaka, Tatsuya Sato, Kei Nakata, Keitaro Nishizawa, Hidemichi Kouzu, Masato Furuhashi

Zitieren

APA

Kawaharata, W., Tanaka, M., Sato, T., Akiyama, Y., Hosaka, I., Aida, H., Matsumori, R., Nakata, K., Nishizawa, K., Suzuki, T., Kouzu, H., Hanawa, N., & Furuhashi, M. (2025). Incorporation of Metabolic Dysfunction‐Associated Steatotic Liver Disease in the Health Stage of Cardiovascular‐Kidney‐Metabolic Syndrome Improves Predictive Ability for Coronary Artery Disease in a Japanese General Population. Journal of the American Heart Association, 14(16). https://doi.org/10.1161/jaha.125.043173

Vancouver

Kawaharata W, Tanaka M, Sato T, Akiyama Y, Hosaka I, Aida H, et al. Incorporation of Metabolic Dysfunction‐Associated Steatotic Liver Disease in the Health Stage of Cardiovascular‐Kidney‐Metabolic Syndrome Improves Predictive Ability for Coronary Artery Disease in a Japanese General Population. Journal of the American Heart Association. 2025;14(16). doi:10.1161/jaha.125.043173

BibTeX
@article{Kawaharata2025,
  author = {Kawaharata, Wataru and Tanaka, Marenao and Sato, Tatsuya and Akiyama, Yukinori and Hosaka, Itaru and Aida, Hiroki and Matsumori, Rie and Nakata, Kei and Nishizawa, Keitaro and Suzuki, Toru and Kouzu, Hidemichi and Hanawa, Nagisa and Furuhashi, Masato},
  title = {Incorporation of Metabolic Dysfunction‐Associated Steatotic Liver Disease in the Health Stage of Cardiovascular‐Kidney‐Metabolic Syndrome Improves Predictive Ability for Coronary Artery Disease in a Japanese General Population},
  journal = {Journal of the American Heart Association},
  year = {2025},
  volume = {14},
  number = {16},
  doi = {10.1161/jaha.125.043173}
}
Kostenlos starten →